T-Capital

T-Capital, also referred to historically as TH Capital and in some databases as Taihecap, is a private China-focused financial services firm rather than a drug developer or healthcare operating company. The firm is described as an investment bank, investment advisory business, and growth equity investor with roots in the Tsinghua University ecosystem and activity centered on high-tech growth sectors in China. Public materials indicate a primary focus on hard-tech areas such as advanced manufacturing, next-generation information technologies, frontier technologies, and decarbonization, although it has also participated in selected healthcare-related investments such as CRO financing rounds. For biotech analysts, the key point is that T-Capital is best understood as a capital provider/advisor that may invest in healthcare businesses, not as a life sciences company with its own therapeutic pipeline.